Mass General study finds normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
- Posted: April 10, 2012
Combining two strategies designed to improve the results of cancer treatment – antiangiogenesis drugs and nanomedicines – may only be successful if the smallest nanomedicines are used. A new study from Massachusetts General Hospital researchers, appearing in Nature Nanotechnology, finds that normalizing blood vessels within tumors, which improves the delivery of standard chemotherapy drugs, can block the delivery of larger nanotherapy molecules.
Among the research institutions NCI funds across the United States, it currently designates 66 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.